NASDAQ:ESPR

Esperion Therapeutics (ESPR) Stock Forecast, Price & News

$0.99

-0.06 (-5.74%)

(As of 09/27/2023 ET)

Compare

Today's Range: $0.97
▼
$1.11
50-Day Range: $0.99
▼
$1.79
52-Week Range: $0.85
▼
$8.87

Volume: 4.42 million shs
Average Volume: 3.29 million shs
Market Capitalization: $105.48 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.88

Esperion Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.56 Rating Score
Upside/Downside: 1,003.1% Upside
$10.88 Price Target
Short Interest: Bearish
15.52% of Float Sold Short
Dividend Strength: N/A
Sustainability: -2.76
Upright™ Environmental Score
News Sentiment: -0.02
Based on 5 Articles This Week
Insider Trading: Selling Shares
$1,438 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.98) to ($0.03) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars

Medical Sector

641st out of 976 stocks

Pharmaceutical Preparations Industry

303rd out of 456 stocks

3.3

Analyst's Opinion

Consensus Rating
Esperion Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 5 buy ratings, 4 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $10.88, Esperion Therapeutics has a forecasted upside of 1,003.1% from its current price of $0.99.
Amount of Analyst Coverage
Esperion Therapeutics has only been the subject of 3 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
15.52% of the float of Esperion Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Esperion Therapeutics has a short interest ratio ("days to cover") of 4.7.
Change versus previous month
Short interest in Esperion Therapeutics has recently increased by 8.43%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Esperion Therapeutics does not currently pay a dividend.
Dividend Growth
Esperion Therapeutics does not have a long track record of dividend growth.

3.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Esperion Therapeutics has received a 53.54% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Ezetimibe", "Clinical research services for pulmonary hearth diseases", and "Bempedoic acid" products. See details.
Environmental Sustainability
The Environmental Impact score for Esperion Therapeutics is -2.76.

1.7

News and Social Media Coverage

News Sentiment
Esperion Therapeutics has a news sentiment score of -0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Esperion Therapeutics this week, compared to 2 articles on an average week.
Search Interest
Only 9 people have searched for ESPR on MarketBeat in the last 30 days. This is a decrease of -55% compared to the previous 30 days.
MarketBeat Follows
6 people have added Esperion Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Esperion Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,438.00 in company stock.
Percentage Held by Insiders
Only 3.30% of the stock of Esperion Therapeutics is held by insiders.
Percentage Held by Institutions
69.76% of the stock of Esperion Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Esperion Therapeutics are expected to grow in the coming year, from ($1.98) to ($0.03) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Esperion Therapeutics is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Esperion Therapeutics is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Esperion Therapeutics (NASDAQ:ESPR) Stock

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

ESPR Price History

30 days | 90 days | 365 days | Advanced Chart

ESPR Stock News Headlines

September 27, 2023 | americanbankingnews.com

Esperion Therapeutics (NASDAQ:ESPR) Stock Passes Below 200 Day Moving Average of $1.51

September 22, 2023 | seekingalpha.com

Esperion Therapeutics Chief Commercial Officer discloses sale of 742 shares

September 27, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.

September 12, 2023 | finance.yahoo.com

American College of Cardiology Program to Increase Cholesterol Screenings

September 1, 2023 | msn.com

Should I load up on Esperion Therapeutics shares under $2?

August 31, 2023 | finance.yahoo.com

Why Is Esperion Therapeutics (ESPR) Down 10.6% Since Last Earnings Report?

August 29, 2023 | msn.com

Esperion Therapeutics: Speculative Buy, Playing The $300 Million Milestone Litigation

August 28, 2023 | msn.com

Why Is Esperion Therapeutics Stock Trading Higher Today?

September 27, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

August 28, 2023 | finance.yahoo.com

Esperion to Participate in H.C. Wainwright 25th Annual Global Investment Conference

August 26, 2023 | finance.yahoo.com

Esperion Presents Two CLEAR Outcomes Study Late-Breakers at European Society of Cardiology Congress 2023

August 11, 2023 | finance.yahoo.com

Two CLEAR Outcomes Study Late-Breakers Accepted at European Society of Cardiology (ESC) Congress 2023

August 9, 2023 | finanznachrichten.de

Esperion Therapeutics, Inc.: Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

August 6, 2023 | finance.yahoo.com

With 77% ownership, Esperion Therapeutics, Inc. (NASDAQ:ESPR) boasts of strong institutional backing

August 3, 2023 | markets.businessinsider.com

5 Analysts Have This to Say About Esperion Therapeutics

August 2, 2023 | msn.com

Needham Maintains Esperion Therapeutics (ESPR) Buy Recommendation

August 2, 2023 | finance.yahoo.com

Esperion (ESPR) Q2 Earnings Top, Stock Up on Strong Revenues

August 1, 2023 | seekingalpha.com

Esperion Therapeutics Q2 2023 Earnings Preview

August 1, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on Esperion (ESPR)

August 1, 2023 | markets.businessinsider.com

Esperion (ESPR) Gets a Buy from JMP Securities

July 24, 2023 | finance.yahoo.com

Esperion to Participate in BTIG Virtual Biotechnology Conference 2023

July 17, 2023 | finance.yahoo.com

Esperion to Report Second Quarter 2023 Financial Results on August 1

July 7, 2023 | finance.yahoo.com

Esperion to Present Additional Data from the CLEAR Outcomes Study on CVD Prevention at the American Society for Preventive Cardiology (ASPC) Congress 2023

June 28, 2023 | finance.yahoo.com

Esperion Announces Submission of Application for Expanded Indication with the European Medicines Agency (EMA) for NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) Tablet

June 26, 2023 | markets.businessinsider.com

Analyst Expectations for Esperion Therapeutics's Future

June 26, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Its Buy Rating for Esperion (ESPR)

June 24, 2023 | finance.yahoo.com

Esperion Presents Results from CLEAR Outcomes Primary Prevention Analysis at 83rd American Diabetes Association Scientific Sessions

See More Headlines

Receive ESPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Esperion Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ESPR Company Calendar

Last Earnings: 8/01/2023
Today: 9/27/2023
Next Earnings (Estimated): 11/07/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ESPR
CUSIP: N/A
CIK: 1434868
Web: www.esperion.com
Phone: (734) 887-3903
Fax: N/A
Employees: 199
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $10.88
High Stock Price Forecast: $22.00
Low Stock Price Forecast: $4.00
Forecasted Upside/Downside: +955.8%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.56
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.82)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-233,660,000.00
Net Margins: -252.82%
Pretax Margin: -252.82%
Return on Equity: N/A
Return on Assets: -84.89%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.17
Quick Ratio: 1.74

Sales & Book Value

Annual Sales: $75.47 million
Price / Sales: 1.46
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($4.39) per share
Price / Book: -0.23

Miscellaneous

Outstanding Shares: 106,990,000
Free Float: 103,463,000
Market Cap: $110.20 million
Optionable: Optionable
Beta: 0.13

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. Sheldon L. Koenig (Age 57)
Pres, CEO & Director
Comp: $1.2M

Mr. Benjamin O. Looker (Age 41)
Gen. Counsel
Comp: $550.35k

Dr. JoAnne Micale Foody FACC (Age 57)
M.D., Chief Medical Officer
Comp: $771.19k

Mr. Benjamin Halladay M.B.A. (Age 37)
Chief Financial Officer

Mr. Glenn P. Brame (Age 65)
Chief Technical Operations Officer

Tiffany Aldrich M.B.A.
Associate Director of Corp. Communications

Ms. Betty Jean Swartz
Chief Strategy Officer

Mr. Eric J. Warren R.Ph. (Age 51)
Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ESPR Stock - Frequently Asked Questions

Should I buy or sell Esperion Therapeutics stock right now?: 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Esperion Therapeutics in the last twelve months. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ESPR shares.
View ESPR analyst ratings or view top-rated stocks.
What is Esperion Therapeutics' stock price forecast for 2023?: 9 analysts have issued 1-year price objectives for Esperion Therapeutics' shares. Their ESPR share price forecasts range from $4.00 to $22.00. On average, they expect the company's share price to reach $10.88 in the next twelve months. This suggests a possible upside of 955.8% from the stock's current price.
View analysts price targets for ESPR or view top-rated stocks among Wall Street analysts.
How have ESPR shares performed in 2023?: Esperion Therapeutics' stock was trading at $6.23 at the beginning of the year. Since then, ESPR shares have decreased by 83.5% and is now trading at $1.03.
View the best growth stocks for 2023 here.
Are investors shorting Esperion Therapeutics?: Esperion Therapeutics saw a increase in short interest in September. As of September 15th, there was short interest totaling 16,460,000 shares, an increase of 8.4% from the August 31st total of 15,180,000 shares. Based on an average daily trading volume, of 3,500,000 shares, the short-interest ratio is presently 4.7 days. Currently, 15.5% of the company's stock are sold short.
View Esperion Therapeutics' Short Interest.
When is Esperion Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our ESPR earnings forecast.
How were Esperion Therapeutics' earnings last quarter?: Esperion Therapeutics, Inc. (NASDAQ:ESPR) issued its earnings results on Tuesday, August, 1st. The biopharmaceutical company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.61) by $0.15. The biopharmaceutical company had revenue of $25.79 million for the quarter, compared to the consensus estimate of $24.64 million. Esperion Therapeutics's revenue for the quarter was up 36.9% compared to the same quarter last year. During the same period last year, the company posted ($1.05) earnings per share.
What is Tim Mayleben's approval rating as Esperion Therapeutics' CEO?: 20 employees have rated Esperion Therapeutics Chief Executive Officer Tim Mayleben on Glassdoor.com. Tim Mayleben has an approval rating of 80% among the company's employees.

What other stocks do shareholders of Esperion Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Esperion Therapeutics investors own include ALDW (ALDW), Targa Resources (TRGP), Navios Maritime Partners (NMM), NVIDIA (nvda), Micron Technology (MU), SFL (SFL), Gilead Sciences (GILD), Boeing (BA), Alibaba Group (BABA) and BioMarin Pharmaceutical (bmrn).
What is Esperion Therapeutics' stock symbol?: Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR."
Who are Esperion Therapeutics' major shareholders?: Esperion Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Wasatch Advisors LP (12.28%), Platinum Investment Management Ltd. (3.24%), Schonfeld Strategic Advisors LLC (1.23%), Braidwell LP (0.84%), Goldman Sachs Group Inc. (0.77%) and Geode Capital Management LLC (0.77%). Insiders that own company stock include Benjamin Looker, Eric Warren, J Martin Carroll, Joanne M Foody, Sheldon L Koenig and Target N V Biotech.
View institutional ownership trends.
How do I buy shares of Esperion Therapeutics?: Shares of ESPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Esperion Therapeutics' stock price today?: One share of ESPR stock can currently be purchased for approximately $1.03.
How much money does Esperion Therapeutics make?: Esperion Therapeutics (NASDAQ:ESPR) has a market capitalization of $110.20 million and generates $75.47 million in revenue each year. The biopharmaceutical company earns $-233,660,000.00 in net income (profit) each year or ($2.82) on an earnings per share basis.
How many employees does Esperion Therapeutics have?: The company employs 199 workers across the globe.
How can I contact Esperion Therapeutics?: Esperion Therapeutics' mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The official website for the company is www.esperion.com. The biopharmaceutical company can be reached via phone at (734) 887-3903 or via email at ir@esperion.com.

This page (NASDAQ:ESPR) was last updated on 9/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial